Please upgrade your browser.
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission;..
Impact of fusion subtype, age, and stage
Portland-area researchers have scored promising results in the hottest field in cancer research today: Using the immune system to fight tumors.
Portland-area researchers harness immune system to shrink tumors
A boy with a rare type of cancer who had his health insurance plan canceled after the Affordable Care Act took effect...
A potential mimic of multilocular cystic renal cell carcinoma
Nephroprotective role of ascorbic acid
Tubulocystic Carcinoma of the Kidney
Is there an association between blood type and prognosis?
|Powered by NeonCRM|